1. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. European urology. 2020;77(4):508-47 .
2. Giona S. The Epidemiology of Prostate Cancer. Exon Publications. 2021:1-15.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
4. Askari F, Parizi M, Rashidkhani B. Dietary patterns and prostate cancer: a case-control study. Iranian Journal of Nutrition Sciences & Food Technology. 2013;8(3):17-25 .
5. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11(5):1388-413.
6. Crawford ED. Epidemiology of prostate cancer .Urology. 2003;62(6):3-12 .
7. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians.2010;60(5):277-300 .
8. Grosclaude P, Belot A, Remontet L, Leone N, Bossard N, Velten M. Prostate cancer incidence and mortality trends in France from 1980 to 2011. Progres en Urologie: Journal de L'association Francaise D'urologie et de la Societe Francaise D'urologie. 2015;25(9):536-42.
9. Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Current oncology reports. 2021;23(2):1-10 .
10. Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate cancer and prostatic diseases. 2021;24(3):623-37 .
11. Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019;10(2):63.
12. Merriel SW, Pocock L, Gilbert E, Creavin S, Walter FM, Spencer A, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of
prostate cancer in symptomatic patients. BMC medicine. 2022;20(1):1-11 .
13. Abbasi M, Basiri S. Prostate Cancer: A Case Report. Journal of Research in Urology. 2017;2(1):29-32 .
14. Koo KM, Mainwaring PN, Tomlins SA, Trau M. Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. Nature Reviews Urology. 2019;16(5):302-17 .
15. Farahmand M, Khademolhosseini F, Mehrabani D. Trend of prostate cancer in Fars Province, Southern Iran, 2001-2007. Journal of research in medical sciences: the official journal of IsfahanUniversity of Medical Sciences. 2010;15(5):295 .
16. Zorlu F, Divrik RT, Eser S, Yorukoglu K. Prostate cancer incidence in Turkey: an epidemiologicalstudy. 2014 .
17. Hosseini M, SeyedAlinaghi SA, Mahmoudi M, McFarland W. A case-control study of risk factors for prostate cancer in Iran. Acta medica Iranica. 2010:61-6 .
18.Chinegwundoh FI. The relationship between Black men with prostate cancer and their health-care providers. Nature Reviews Urology. 2021;18(12): 701-2 .
19.Sivoňová MK, Kaplán P, Tatarková Z, Lichardusová L, Dušenka R, Jurečeková J. Androgen receptor and soy isoflavones in prostate cancer. Molecular and clinical oncology. 2019;10(2):191-204 .
20. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. European urology. 2020;77(1):38-52 .
21. Rafimanesh H, Ghoncheh M, Salehinia H, Mohammadian Hafashjani A. Epidemiology of prostate cancer and its incidence trends in Iran. Journal of Sabzevar University of Medical Sciences. 2016;23(2):320-7
)